CellCentric Company
CellCentricвАЩs primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
Total Funding:
$42.6M
Headquarters:
Cambridge, Cambridgeshire, United Kingdom
Funding Status:
N/A
Employee Number:
1-10
Estimated Revenue:
$10M to $50M
Investment Stage:
N/A
Last Funding Type:
Venture - Series Unknown
Number Of Exists:
Venture - Series Unknown
Technology:
Data-driven Technologies
Investor Type:
Company
Investors Number:
9
Founded Date:
2003
Industry:
PharmTech